154 related articles for article (PubMed ID: 22426845)
1. Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: double blind, cross-over glucose clamp study.
Kopf D; Gilles M; Paslakis G; Medlin F; Lederbogen F; Lehnert H; Deuschle M
Pharmacopsychiatry; 2012 Sep; 45(6):223-8. PubMed ID: 22426845
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.
Chintoh AF; Mann SW; Lam L; Lam C; Cohn TA; Fletcher PJ; Nobrega JN; Giacca A; Remington G
J Clin Psychopharmacol; 2008 Oct; 28(5):494-9. PubMed ID: 18794643
[TBL] [Abstract][Full Text] [Related]
3. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model.
Hahn MK; Chintoh A; Remington G; Teo C; Mann S; Arenovich T; Fletcher P; Lam L; Nobrega J; Guenette M; Cohn T; Giacca A
Eur Neuropsychopharmacol; 2014 Mar; 24(3):448-58. PubMed ID: 24001874
[TBL] [Abstract][Full Text] [Related]
4. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers.
Wetzel H; Wiesner J; Hiemke C; Benkert O
J Psychiatr Res; 1994; 28(5):461-73. PubMed ID: 7897617
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.
Sowell MO; Mukhopadhyay N; Cavazzoni P; Shankar S; Steinberg HO; Breier A; Beasley CM; Dananberg J
J Clin Endocrinol Metab; 2002 Jun; 87(6):2918-23. PubMed ID: 12050274
[TBL] [Abstract][Full Text] [Related]
6. Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.
Mortimer AM; Joyce E; Balasubramaniam K; Choudhary PC; Saleem PT;
Hum Psychopharmacol; 2007 Oct; 22(7):445-54. PubMed ID: 17691076
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls.
Hahn MK; Wolever TM; Arenovich T; Teo C; Giacca A; Powell V; Clarke L; Fletcher P; Cohn T; McIntyre RS; Gomes S; Chintoh A; Remington GJ
J Clin Psychopharmacol; 2013 Dec; 33(6):740-6. PubMed ID: 24100786
[TBL] [Abstract][Full Text] [Related]
8. Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion.
Roix JJ; DeCrescenzo GA; Cheung PH; Ciallella JR; Sulpice T; Saha S; Halse R
Diabetes Obes Metab; 2012 Apr; 14(4):329-34. PubMed ID: 22059694
[TBL] [Abstract][Full Text] [Related]
9. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
[TBL] [Abstract][Full Text] [Related]
10. Amisulpride: a review of its use in the management of schizophrenia.
McKeage K; Plosker GL
CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
[TBL] [Abstract][Full Text] [Related]
11. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects.
Mattila MJ; Patat A; Seppälä T; Kalska H; Jalava ML; Vanakoski J; Lavanant C
Eur J Clin Pharmacol; 1996; 51(2):161-6. PubMed ID: 8911882
[TBL] [Abstract][Full Text] [Related]
12. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model.
Chintoh AF; Mann SW; Lam L; Giacca A; Fletcher P; Nobrega J; Remington G
Schizophr Res; 2009 Mar; 108(1-3):127-33. PubMed ID: 19157785
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice.
Pawar GR; Agrawal RP; Phadnis P; Paliwal A; Vyas S; Solanki P
Acta Pol Pharm; 2009; 66(3):327-31. PubMed ID: 19645334
[TBL] [Abstract][Full Text] [Related]
15. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
16. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.
Peuskens J; De Hert M; Mortimer A;
Int Clin Psychopharmacol; 2007 May; 22(3):145-52. PubMed ID: 17414740
[TBL] [Abstract][Full Text] [Related]
17. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers.
Sacher J; Mossaheb N; Spindelegger C; Klein N; Geiss-Granadia T; Sauermann R; Lackner E; Joukhadar C; Müller M; Kasper S
Neuropsychopharmacology; 2008 Jun; 33(7):1633-41. PubMed ID: 17712347
[TBL] [Abstract][Full Text] [Related]
18. Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia.
Rickels MR; Perez EM; Peleckis AJ; Alshehabi E; Nguyen HL; Stefanovski D; Rickels K; Teff KL
Am J Physiol Endocrinol Metab; 2018 Aug; 315(2):E250-E257. PubMed ID: 29351487
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders.
Literáti-Nagy B; Péterfai E; Kulcsár E; Literáti-Nagy Z; Buday B; Tory K; Mandl J; Sümegi B; Fleming A; Roth J; Korányi L
Brain Res Bull; 2010 Nov; 83(6):340-4. PubMed ID: 20849938
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance following continuous, chronic olanzapine treatment: an animal model.
Chintoh AF; Mann SW; Lam TK; Giacca A; Remington G
Schizophr Res; 2008 Sep; 104(1-3):23-30. PubMed ID: 18675538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
